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ABSTRACT
Introduction The HORIZON 2020 project PoCOsteo aims 
(1) to develop a multidimensional fracture risk assessment 
tool which would take into account all factors known to be 
related to an individual’s fracture risk. The fracture risk model 
is intended to be developed in two different populations, 
namely a European and a Middle Eastern one; (2) to develop 
a medical device, which would measure and/or quantify 
proteomic as well as genomic factors as present in whole 
blood samples collected through finger prick; (3) to test the 
clinical applicability and the validity of prototypes of the to be 
developed point of care device at both clinical centres.
Methods and analysis This article presents the protocol of 
this prospective cohort that will be carried out independently 
at two different centres (Division of Endocrinology and 
Diabetology at the Medical University of Graz (MUG) as a 
clinic- based cohort, and Endocrinology and Metabolism 
Research Institute (EMRI) at the Tehran University of Medical 
Sciences (TUMS) as a population- based cohort). The final aim 
is to develop a fracture risk assessment model, which would 
include clinical risk factors, biochemical markers of bone 
turnover, as well as specific genomic factors. The derivation 
cohorts will consist of individuals aged 50 years and above. 
The period of observation for each patient will be 12 months; 
an extension phase, which would last for another 2 years, is 
also planned.
Ethics and dissemination These studies are conducted in 
accordance with the World Medical Association Declaration 
of Helsinki. The Iranian part was approved by the Research 
Ethics Committee of EMRI, TUMS. The Austrian part was 
approved by the Ethics Committee of the Medical University of 
Graz. Based on the gathered information, a multidimensional 
fracture assessment tool will be designed which will later be 
added to the PoCOsteo device.
INTRODUCTION
Background and rationale
The world population is ageing rapidly. The 
proportion of individuals aged over 60 years 
will double, from about 11% to 22% between 
2000 and 2050, suggesting that about 2 billion 
individuals are expected to be over 60 years in 
2050.1
The rise in the number of the elderly high-
lights the surging need for understanding the 
impact and consequences of ageing as well as 
the necessity to research into the prevention 
Strengths and limitations of this study
 ► The multicentric cohort design of the study will allow 
the recruitment of a large group of diverse individ-
uals. This will improve not only the knowledge on 
osteoporosis and osteoporotic fracture but also the 
validity and generalisability of the to be developed 
multidimensional fracture assessment tool. In other 
words, this is one of the few studies to be conducted 
on a European and Middle Eastern population using 
a nearly similar protocol. And therefore, provides a 
unique opportunity for the investigators to compare 
their findings in the two studied populations.
 ► Moreover, nowadays, no fracture risk assessment 
tool based on fracture risk- related proteomic, ge-
nomic and clinical factors exists to our knowledge. 
The modelling to be developed in this study will be 
the first in this regard.
 ► The additional amount of blood stored in the bio-
banks during the research will provide an exception-
al chance to study other factors yet to be determined 
in future projects.
 ► The difference in the nature of the study populations 
between the two centres could result in some dis-
parities in the results. As the subjects are collected 
from a single centre in each continent, the gener-
alisability of the results to the whole European and 
Middle Eastern population might not be possible. As 
the study is conducted on the elderly population, lost 
to follow- up due to underlying health conditions and 
death is inevitable.
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and management strategies for non- communicable 
diseases (NCDs).
To achieve these goals, research into the health prob-
lems of the elderly and preserving their quality of life and 
independence has become a top priority in many health 
settings.2 Physical disability and cognitive impairment are 
the two main risks that threaten the independence of the 
elderly. The former is commonly caused by musculoskel-
etal disorders such as osteoporosis.3–6
Osteoporosis is frequently referred to as a ‘silent 
disease,’ indicating that the development of the disease 
may remain unrecognised until the first fracture occurs.7 
Osteoporosis and related fractures impose a heavy socio-
economic burden and are thus considered as a major 
health concern in many countries worldwide. So far, no 
easily accessible and widely available methods with suffi-
cient sensitivity for early detection of osteoporosis have 
been developed.
In 2010, 22 million women and 5.5 million men were 
estimated to have osteoporosis in the EU. In the same 
year, about 3.5 million new fragility fractures were 
sustained in different member states.8 These fractures 
accounted for 1 180 000 quality- adjusted life- years 
(QALY) lost and were estimated to impose a burden 
of about €37 billion. In 2025, these costs are expected 
to increase by 25%. Iran, as well, is affected by this 
phenomenon with the disease depriving Iranians of 
36’026 healthy years of life (18 757 in men and 17 270 
in women) in 2001.9 10
Currently, the gold- standard and the validated method 
to investigate osteoporosis is dual energy X- ray absorp-
tiometry (DXA), which is usually available in tertiary 
or imaging centres. While there is good evidence that 
low bone mineral density (BMD) is associated with an 
increase in fracture risk, the sensitivity of this method 
to detect at- risk individuals is below 50% and more than 
one- third of fractures occur in individuals with normal 
BMD.11 Moreover, improvements in bone density appear 
in DXA after 2 years, which devalues DXA as a monitoring 
tool. On the other hand, the test is expensive with a range 
of €48 to some €300. The annual costs from a screening 
visit to the full investigation are calculated to round up 
at around €44 000–€88 000/QALY.12 This figure high-
lights the need for better vetting of the patients who are 
referred for imaging to maximise the cost- effectiveness 
while protecting the patients against unnecessary expo-
sure to X- ray radiation.
Bone turnover biomarkers (BTMs), such as osteo-
calcin (OC), C- terminal telopeptide of type I procollagen 
(CTx), N- propeptide of type I procollagen (PINP), bone- 
specific alkaline phosphatase (bALP) or tartrate- resistant 
acid phosphatase (TRAP), on the other hand, provide 
useful information on the momentary balance between 
bone formation and resorption and thus fracture risk, 
particularly in postmenopausal women.13 However, utili-
sation of these markers is very limited due to their prean-
alytical and analytical variability along with the need for 
expensive and sophisticated laboratory equipment, such 
as ELISA or electrochemiluminescence- immunoassay 
(ECLIA).
In recent years, genetic variability has also been shown 
to be related to an individual’s fracture risk and/or BMD 
values; as a result, the measurement of parameters such 
as single- nucleotide polymorphisms (SNPs) and micro 
RNAs are becoming more important. This is while their 
measurement is limited to few and highly specialised 
centres as not only it requires highly specialised personnel, 
but even more sophisticated and more expensive labora-
tory equipment compared with the biochemical markers.
Apart from these variables, clinical risk factors (CRFs) 
play a pivotal role in predicting an individual’s absolute 
fracture probability. As a result, CRFs have been inte-
grated into a variety of fracture risk assessment tools such 
as FRAX and QFracture.14 15 Nevertheless, no fracture 
risk assessment tool taking into account proteomic and 
genetic factors is currently available.
The PoCOsteo project is an EU- funded H2020 project, 
designed to achieve this goal by providing the physicians 
with a tool to perform an individual risk assessment for 
each patient while bringing together biomarker measure-
ment, profiling of genetic variations and assessing the 
underlying risk factors. This approach will enhance 
the predictive accuracy of fracture risk and provide the 
affected individuals with personalised care even in rural 
areas, where access to current state- of- the- art equipment 
is limited. This real- time measurement device will also 
revolutionise the treatment monitoring process, making 
it more efficient while reducing the low- compliance rate 
commonly reported in osteoporotic patients.16 The Inter-
national Osteoporosis Foundation (IOF), an interna-
tional non- governmental organisation with the mission 
to advance the understanding of osteoporosis and to 
promote prevention, diagnosis and treatment of the 
disease worldwide, supports the project.
Specific aims
The overall aim of this project is to develop a multidi-
mensional fracture risk assessment model and validate it 
in practice. In brief, the device will measure both BTMs 
and genetic factors using a finger prick blood sample.17 It 
then integrates the respective results into an algorithm, 
which also accounts for CRFs to estimate an individual’s 
risk of developing a fracture.
To detect possible population- specific differences, data 
derivation cohorts are recruited in parallel but inde-
pendently at two different study centres, namely the 
Medical University of Graz, representing a European 
population, and the Endocrinology and Metabolism 
Research Institute (EMRI), Tehran University of Medical 
Sciences (TUMS), representing a Middle- Eastern 
population.
The clinical studies also aim at investigating the prev-
alence and incidence of osteoporosis and osteoporotic 
fracture as well as their risk factors in the elderly popula-
tions. They also assess possible preanalytical variability in 
BTM measurement.
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These clinical studies also provide the opportunity for 
the PoCOsteo device to be tested in a clinical environ-
ment to determine its diagnostic accuracy in measuring 
the BTM levels and detecting selected genes in compar-
ison with ECLIA and PCR, respectively. They also help 
with calculating the diagnostic value of the PoCOsteo 
device in predicting individual fracture risk and moni-
toring osteoporosis treatment in comparison to DXA.
STUDY DESIGN
As mentioned earlier, this prospective multicentric cohort 
study is conducted in two different study centres. Despite 
the differences in the recruited population, the study 
protocols are congruent so that the final results would 
be comparable. Using a cohort approach, data for each 
centre are collected from the beginning of spring 2018 
and the subjects will be followed up to 3 years or at least 
until the end of the project in autumn 2021 (The device 
will be applied in real time to a subsample of the collected 
blood samples at Year 3. Moreover, after Year 3, all Iranian 
participants will be followed according to the Bushehr 
elderly health (BEH) protocol). A schematic diagram of 
the study design and the tests to be performed at each 
visit is illustrated in figure 1.
Study population
The target population of this study is recruited from two 
study sites with two different approaches.
Iran: Bushehr elderly health programme
BEH is a prospective cohort study conducted by the 
EMRI of TUMS and Persian Gulf Marine Biotechnology 
Research Centre (PGTMRC) with the aim of investigating 
the prevalence of NCDs in an elderly population.18 The 
current study is designed as an extension to the second 
stage of BEH and will mainly focus on musculoskeletal 
diseases (in line with the main objective of PoCOsteo).
Two thousand new subjects are enrolled through the 
same method used in the previous stage of the BEH 
programme. In brief, the participants are selected 
through a multistage, stratified cluster random sampling 
method. Based on the classifications made by the Bushehr 
municipality, the city is stratified into 75 strata. Numbers 
are assigned to the blocks (as clusters) of each stratum 
and then randomly selected. All eligible people residing 
in each selected block will be invited until the determined 
sample size for that stratum is reached. This number is 
calculated proportionally to the number of households 
residing in each stratum.
Both male and female participants aged 50 years and 
over who have resided in Bushehr port for at least 1 year 
prior the recruitment and have no plan to leave the city 
for at least the next 5 years and agree to be part of the 
study will be recruited. Those with a positive history of 
bilateral hip replacement surgery or not having adequate 
physical and mental ability to participate in the evalua-
tion programme will be excluded.
The invitations will be presented to all the randomly 
selected households with inhabitants meeting the age 
criteria through a door- to- door household visit. They 
contain instructions on how to contact the research 
organisation and the responsible staff to participate in 
the study.
An android application is developed to manage invita-
tions based on national ID codes. The participants who 
have been invited to participate in the previous stage of 
BEHP will be removed from the invitation list.
Austria: Graz study
The Graz study is similarly designed as a prospective 
cohort study but will be carried out at the outpatient 
osteoporosis clinic of the Division of Endocrinology and 
Diabetology in the University Hospital of Graz. All women 
and men 50 years and above who are referred to the oste-
oporosis clinic will be asked to participate in this study.
Initial assessment
The participants from both centres who meet the study 
inclusion criteria will be informed in more detail about 
the purpose and the cornerstones of the present study. 
Figure 1 Tasks to be completed at each visit during the BEH stage two study and Graz. CRFs, clinical risk factors; BEH, 
Bushehr elderly health; BMD, bone mineral density; HR- pQCT, high- resolution peripheral CT; miRNAs, micro RNS; SNPs, single- 
nucleotide polymorphisms; VFA, vertebral fracture assessment.
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After having obtained a written informed consent from 
the respective patient, the study nurse will start collecting 
the baseline data including anthropometric parameters 
and CRFs known to be associated with fracture risk. A base-
line BMD and vertebral fracture assessment (VFA) will be 
also performed. A subgroup of the Austrian subjects will 
also be selected to undergo high- resolution peripheral 
CT (HR- pQCT). Thereafter, blood will be drawn from a 
cubital vein of each patient.
Based on previous studies, we assume a prevalence 
of about 30% for osteoporosis, indicating that approxi-
mately 600 individuals will be diagnosed with osteoporosis 
at baseline.19 20 This subpopulation along with those diag-
nosed with osteoporosis during the study will be referred 
to a specialist with ample experience in managing osteo-
porosis. The research nurse will also follow these partic-
ipants. She/he will also follow the occurrence of main 
outcomes (mortality, hospital admissions and fractures) 
for all participants periodically through phone calls.
Follow-up assessments
The first follow- up visit will take place 12 months after 
recruitment. Shortly before the end of year 1, the study 
nurse will contact the respective patients and invite them 
to the follow- up visit. In case a patient is unreachable, the 
study coordinator will be contacted for further action.
During this follow- up, the study nurse will take history 
and report any relevant information. Venous blood will 
be drawn (from a cubital vein) and a follow- up BMD 
and VFA, and, if applicable, a follow- up HR- pQCT will 
be performed. In case the project consortium decides to 
extend the clinical study, 2- year and/or 3- year follow- up 
visits will be conducted.
At the beginning of year 4, the PoCOsteo device will be 
ready for use and thus the BTM measurements and SNP 
studies will be performed in real- time using the device in 
a subsample of the study population (both osteoporotic 
and non- osteoporotic subjects). The results will be then 
compared with the respective gold- standard methods 
(ECLIA for biochemical markers and PCR for genetic 
markers).
Patient and public involvement
As mentioned earlier, research on health problems of the 
elderly and preserving their quality of life and indepen-
dence has become a top priority in many health settings 
and thus the present study was designed to address these 
concerns and to improve the subjects’ quality of life. The 
subjects were not involved in the design of the current 
study, but the lessons learnt from previous studies, 
including their preferences, were taken into account 
while drafting this protocol. The recruited subjects will be 
presented with the results of their tests and in case further 
consultation/treatment is needed, additional sessions will 
be arranged. Moreover, the subjects will also be educated 
about osteoporosis and its risk factors during these meet-
ings to improve their awareness.
DATA STORAGE AND MANAGEMENT
Data collection
Patient- specific data will be collected and documented in 
the case report forms at the time of each visit, and within 
a week after the results of the diagnostic workups become 
available to entail all necessary variables. The information 
to be included in the case report forms include:
Clinical risk factors
Together with the patient’s history, CRFs known or 
suspected to be associated with an individual’s absolute 
risk of osteoporotic fractures (table 1) will be determined 
and documented. CRFs will include variables, which are 
an integral part of the FRAX tool, among others.
Biological samples
Some 20 mL of venous blood will be drawn. Blood samples 
will be dissociated into cells and sera on- site within 20 
min after collection and analysis will be performed on 
the same day. This protocol will be closely followed as the 
time to dissociation influences the results, especially OC 
levels.
After the initial analysis, the dissociated sera and 
the whole blood samples will be stored at −80°C in the 
PGTMRC biobank (Bushehr, Iran) before being trans-
ferred to the EMRI biobank (Tehran, Iran) for further 
analysis and storage at the same conditions. As for Graz, 
Austria, the samples will all be stored in the Graz Univer-
sity biobank.
In both centres, blood samples will be collected in the 
morning after 8–12 hours of fasting. About 16 mL of 
the collected blood will be stored in an evacuated tube. 
Nine mL will be stored in three evacuated tubes with 
Ethylenediaminetetraacetic acid (EDTA) for complete 
blood count (CBC) analysis, Hemoglobin A1C (HbA1C) 
measurement, and dissociation of plasma, respectively. 
The clot will be divided into 10 parts, 6 of which will be 
used for the tests mentioned in table 2 and the remaining 
four will be stored in the biobank. Two cryovials of plasma 
and three cryovials of whole blood along with an extra 
Pax tube will be stored in the biobank as well.
The BTM measurements will be done in both centres 
using ECLIA (Roche, Cobas) and similar kits. The genetic 
variability will be assessed by measuring the presence of 
specific SNPs in the blood samples using PCR.
Imaging
 ► BMD measurement is performed using GE Lunar 
iDXA for the Austrian study and Hologic DXA (DXA 
Discovery WI, Hologic, Bedford, Virginia, USA) for 
the Iranian site. To have comparable results, similar 
phantoms will be used at both sites to calibrate the 
devices.
 ► VFA to be implemented on the DXA machines.
 ► HR- pQCT (SCANCO Xtreme CT, II Generation) of 
the lower limb will be performed in a small subgroup 
of the Austrian patients (n=50; 25 with prevalent 
osteoporotic fracture and 25 as controls).21
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Data Handling and storage
All data- related issues will be handled according to the 
current version of the General Data Protection Regula-
tion. Participants will be given a unique code to protect 
their identity in any future utilisation of the database. 
These codes will be used in labelling the case report 
forms and the digital spreadsheet database as well as all 
collected blood samples and dissociated sera to ensure 
anonymity. Only specified research team members can 
access these data.
To ensure minimal data loss, case report forms will 
be completed during each visit. As for the Iranian part, 
interim analysis to investigate participation and dropout 
rate as well as outlier detection, will be conducted every 3 
months to allow timely corrective interventions to prevent 
data loss.
OUTCOMES AND ANTICIPATED RESULTS
Prevalent non-vertebral and vertebral fractures
The primary outcome of interest is to determine the 
number of non- vertebral and vertebral fractures in each 
population. This is done during history taking.
The age- specific hip fracture incidence in the Austrian 
50+ female and male population is about 650/and 
250/100 000, respectively.22 It can, thus, be anticipated 
that about 10 hip fractures (7 in women and 3 in men) 
occur within 1 year in the 1000 participants of the current 
study. As for Iran, the annual incidence of hip fracture 
per 100 000 person- years is 115.2 (95% CI 107.2 to 123.7) 
in men and 115.6 (95% CI 107.4 to 124.3) in women.23
It should be noted that these estimates might be an 
overestimation mainly in the Austrian arm because most 
of the patients referred to the study centre are already 
Table 1 Information to be collected in clinical studies through CRFs, physical examination and para clinics
CRF Interview Age, gender, smoking status (amount and duration), alcohol consumption status (amount, 
type and duration), history of fracture (low impact/due to trauma and site), secondary causes 
of osteoporosis (due to diseases impacting bone health (Chronic Obstructive Pulmonary 
Disease (COPD), Epilepsy, Dementia, Parkinson‘s disease, Malignancies, systemic lupus 
erythematosus, Rheumatoid arthritis, chronic kidney disease diabetes, …), history of fall, and/or 
medication affecting bone health (Parkinson medication, dementia medication, antidepressants, 
anticonvulsants …)), parental history of hip fracture, glucocorticoid treatment (>3 months and >5 
mg prednisolone equivalent). (As for the Iranian part, considering the main objectives of the BEH, 
cardiovascular risk factors and cognitive function will also be studied. Information on the subjects’ 
socioeconomic status, illicit drug abuse status, physical activity, reproductive information, and 
duration and amount of sun exposure per day, history of hospital admissions in the previous year 
(cause and duration), cognitive function and dietary assessment will be collected).
Questionnaire Activities of daily living (ADL) and instrumental ADL, Patient Health Questionnaire-9, health- related 
quality of life (EuroQoL- 5D (EQ- 5D)), Short Physical Performance Battery, and Minimal Mental 
State Examination questionnaires, as well as 6- item Cognitive Impairment Test (As for the Austrian 
subjects, the Short Form Health Survey-12 (SF-12) Quality of Life questionnaire will be filled out).
Physical examination Anthropometric measurement (weight, height, length of the leg and right arm, and neck, hip, waist, 
right arm, right femur circumference), blood pressure, the muscular mass, and force evaluation, 
and evaluation of gait and stance (capability to lift 10- pound weight, capability to walk, capability 
to get up from a chair/bed, capability to climb a 10- step staircase, time to walk 4.75 m in seconds, 
time to stand up from sitting position in seconds, time to walk 2.44 m in seconds, feet together 
stance, semi/full tandem stance for 10 s).
BEH, Bushehr elderly health; CRFs, clinical risk factors.
Table 2 Tests to be performed in each centre
Routine parameters Full blood count, fasting blood sugar, HbA1c, renal parameters, hepatic parameters, C 
reactive protein, protein electrophoresis, electrolytes including magnesium, lipid profile 
including high-/low- density lipoprotein -cholesterol
Bone- specific biomarkers Osteocalcin; carboxyl- terminal telopeptide of type I collagen; bone- specific alkaline 
phosphatase; tartrate- resistant acid phosphatase; N- propeptide of type I collagen; 
25- hydroxyvitamin D; Intact parathyroid hormone
Hormones (optional—depending 
on indication)
Follicle- stimulating hormone, Luteinising hormone, estradiol, testosterone
Genetic factors Single- nucleotide polymorphisms
Others (These parameters are only 
tested in Austria optionally and 
depending on the coverage of 
thecost)
Fibroblast Growth Factor 23(FGF 23), Myostatin, Sclerostin
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suspected of having osteoporosis. On the other hand, this 
number could also be an underestimation because some 
of the patients referred to the study centre might have 
already received treatment for osteoporosis. It should be 
noted that the total number of fracture observed within 1 
year is largely dependent on the proportion of male and 
female study participants.
As many of the patients will not be able to provide reli-
able information on the exact fracture location and/or 
type, verification will be performed by requesting the 
original patient report and/or the original radiograph. 
Furthermore, the exact date of the fracture will be deter-
mined, as it affects future fracture risk, which would be 
highest within the first year after a fracture.
Strong epidemiological evidence indicates that the 
majority of osteoporotic fractures occur at the thoracic 
and the lumbar spine. However, only around one- third 
of these fractures come to clinical attention.24 It has also 
been estimated that about seventy per cent of all vertebral 
fractures remain undetected if no imaging of the spine 
is performed. To obtain reliable baseline data regarding 
prevalent vertebral fractures, VFA will be used.25 The 
already available thoracic and lumbar spine radiographs 
will be accepted for data entry if the radiographs have 
been taken within the past 6 months before recruitment.
Bone mass
Identifying osteoporotic patients through measuring 
their bone mass is the second outcome of interest. BMD 
measurement is widely recommended by the respective 
scientific societies worldwide as part of the baseline exam-
inations if osteoporosis is suspected.26 As mentioned 
earlier, DXA is the method of choice and so all patients 
will undergo BMD measurement of the lumbar spine and 
the hip.26 HR- pQCT will be performed for a subgroup of 
Austrian subjects to provide more accurate information 
on their bone structural parameters.
Proteomic parameters
BTMs have been shown to provide relevant information 
on the extent of bone resorption and bone formation.27 
In a position paper published by the IOF, the biomarker 
taskforce has recommended the use of CTx and PINP 
as reference markers for all clinical studies, adding one 
of these markers is sufficient for daily clinical practice 
measurements.28 It is noteworthy that irrespective of 
BTMs being associated with an individual’s fracture risk, 
such markers are currently not included in any avail-
able fracture risk assessment tool. Possible reasons are 
the considerable diurnal variability of such markers and 
the fact that their significance in men is less well investi-
gated compared with women.27 As a result, bone resorp-
tion markers including CTx and TRAP, as well as bone 
formation markers including OC, PINP and bALP will 
be measured in this study. A modelling algorithm (to be 
discussed later) will be applied to reduce the preanalyt-
ical variability.
Genetic variability
Recently, research activities concerning alternative 
circulating markers that could provide information 
on a person’s fracture probability, such as SNPs have 
increased. In one of the largest meta- analyses performed 
on SNPs so far, it was found that about 56 gene loci are 
associated with BMD; of those about 14 are linked with 
fracture risk.29 30 Despite these findings, these markers 
have never been integrated into any of the available 
assessment tools, possibly due to their modest effect 
size on fracture risk (ORs ranging from 1.03 to 1.10).31 
Detecting SNPs that will later be used in the fracture 
risk assessment tool, therefore, is an integral part of the 
prevailing project.
PROPOSED STATISTICAL METHODS
Quantitative data will be described as mean±SD for 
normally distributed data, based on the Shapiro- Wilk test, 
while non- normal variables will be presented as median 
(IQR: P25–P75). Categorical data will be explained by 
percentages and will be tested using χ2, Fisher’s exact. 
Between- group differences will be analysed using one- way 
analysis of variance, Student's t- test, Kruskal- Wallis and 
Mann- Whitney U tests, where indicated.
Incidence rates of osteoporosis and sarcopenia will be 
estimated per 1000 person- years. Also, relative risk, OR 
and HR with 95% CIs will be calculated to show the asso-
ciation of risk factors of interest with the outcomes. In the 
modelling of hip fracture, penalised methods will be used 
to alleviate probable overfitting due to possible small 
number of events per parameters. The optimism and 
the optimism- corrected performance will be calculated 
using bootstrap resampling methods to prevent overfit-
ting. As cohorts can be considered as the strata, k- fold 
cross- validation techniques will be applied to compare 
the results.
Pearson’s and Spearman’s correlation coefficients 
will be used to present the correlation between contin-
uous variables. Multiple linear regression analysis will be 
used to assess the association of continuous dependent 
variables with their potential risk factors. In the case of 
a dichotomous outcome, binary logistic regression or 
modified Poisson will be used.
To analyse the survival rates, the life table and Kaplan- 
Meier method will be used. Cox- proportional hazard 
models or other appropriate multivariable survival 
methods will be used to adjust for potential confounders.
As it is inherent in any cohort design, different correla-
tions might be extracted from the studied population. It is 
therefore routine to use sex and age as covariates, as long 
as they are not separately correlated with the outcome 
of desire. However, other factors such as cognitive status 
may also be considered as covariates in more complex 
models. Choosing covariates will be carried out following 
the Hosmer- Lemeshow guidelines and referencing the 
previous body of evidence.
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Device accuracy
As for the PoCOsteo device, the agreement between 
the results measured using PoCOsteo and the gold stan-
dard methods (ECLIA and PCR) will be studied. Sensi-
tivity, specificity and the 95% CIs for all comparisons will 
be calculated; these measures may need to be stratified 
based on factors such as gender or age. To assess the 
agreement between standard methods and results of this 
study, the Bland- Altman graph and Cohen’s kappa coef-
ficient (κ) will be applied. A receiver operating charac-
teristic analysis will be conducted to provide insight on 
optimal thresholds for PoCOsteo measurements. The 
curves, their coordinates and diagnostic measures will be 
reported.
Missing values will be replaced using multiple impu-
tations through multiple regression method. In case of 
death, the data that should have been collected in the 
subsequent time points, will be censored at the final visit 
point.
Modeling plans
To provide a holistic statistical model that compensates 
for the preclinical variability of BTMs, variables such 
as age, previous medical and fracture history, and life-
style measures (such as physical activity, dairy intake 
and alcohol consumption) along with BTMs and serum 
calcium and 25- hydroxyvitamin D levels will be used.
First, the correlation between each of the aforemen-
tioned variables with each marker will be assessed. This is 
followed by the application of linear regression models to 
study the correlation direction between the variables and 
its effect size. The final goal will be to compensate for the 
preclinical variability of BTMs.
A second modelling will be built to predict fracture 
risk using biomarker levels, genetic variability and CRFs, 
and illustrate a better outlook on how well using BTMs 
will assist clinical detection of high- risk patients. In this 
regard, data mining methods such as logistic regression, 
generalised boosted models, Artificial Neural Network 
and Super learner and Swiss Cheese Model will be applied.
Since overfitting is a central problem in prediction 
modelling, the validity of the model will be tested in 
new patients. In this regard, the ability of the device in 
predicting osteoporotic fracture will be tested after inte-
grating this equation model into the PoCOsteo tool. At 
this point, DXA will serve as the gold standard for diag-
nosing osteoporosis. In other words, in the modelling 
phase, the existing dataset will be used as the training set 
and will be validated using those collected in this study.
Sample size
The prevalence of osteoporosis in BEH Cohort is about 
28.8% and the overall prevalence of osteoporosis in Iran 
is reported to be 15%. Based on the amount of squared 
multiple correlations between predictors and consid-
ering the attrition rate of about 10%, 1628 individuals are 
needed for the Iranian part. However, considering the 
population- based nature of this arm, a total sample size 
of 2000 individuals including 500 osteoporotic and 1500 
healthy participants will be needed.
As for Austria, the prevalence of osteoporosis is about 
8%. At the same time, the risk of experiencing and not 
experiencing fracture is 1.15% and 0.38%, respectively. 
Considering the attrition rate of about 10%, 1131 subjects 
are needed.
ETHICS AND DISSEMINATION
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The Iranian part was approved by the Research Ethics 
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by the Ethical Board Committee of Graz University of 
Medical Sciences (30–246 ex 17/18).
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